Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole with or without local 3D conformal radiotherapy for oligometastatic hormone-sensitive breast cancer
ISRCTN15692114Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Oct 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of letrozole in breast cancer (2 arms), sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: One-year progression-free survival rate. Started Oct 2005; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN15692114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15692114.